The efficiency, low toxicity and high tumor-to-healthy tissues uptake ratio associated with Bip-125 I-35A7-RIT suggest that this methodology could be used in 3 combination with radiation synergistic drugs in the therapy of small volume peritoneal carcinomatosis following cytoreductive surgery.
Conclusion:
The efficiency, low toxicity and high tumor-to-healthy tissues uptake ratio associated with Bip-125 I-35A7-RIT suggest that this methodology could be used in 3 combination with radiation synergistic drugs in the therapy of small volume peritoneal carcinomatosis following cytoreductive surgery.
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INTRODUCTION
Peritoneal carcinomatosis is a common evolution of gastrointestinal or gynecological tumors, or of primary peritoneal malignancy like mesotheliomas or peritoneal serous carcinoma.
Peritoneal carcinomatosis has been considered for long time as a terminal disease with a median survival ranging between 12 and 23 months for patients with stage IV ovarian cancer, about 6 months for colorectal carcinoma, 3 for gastric cancer, 2 for pancreatic cancer and only 1.5 months for carcinomatosis from unknown primary cancer (for reviews (1, 2) ). The therapeutic approach is based on palliative systemic chemotherapy and surgery is mainly used in palliative intention, according to symptoms, except in the case of ovarian cancer where complete cytoreduction is part of the standard therapeutic regimen. Twenty years ago, Sugarbaker introduced cytoreductive surgery (CRS) to resect the visible disease combined with hyperthermic intraperitoneal chemotherapy (HIPEC) to treat the residual disease, as an innovative therapeutic option for selected patients with peritoneal carcinomatosis (3, 4) . CRS procedure depends on the extent of the peritoneal disease and the chemotherapy protocols may include mitomycin C, oxaliplatin, mitoxantrone, cisplatin and irinotecan alone or in combination (for reviews (1, 2) 6 ) and for reviews (1, 2) ). Although mortality is relatively low, morbidity results from surgery complications and/or from toxicity (such as leucopenia, anemia, thrombopenia, heart, liver or renal toxicity) due to the cytostatic agents (for reviews (1, 2) ).
Several studies in rodents have shown that radioimmunotherapy (RIT) could be used efficiently as an adjuvant treatment after CRS for the treatment of peritoneal carcinomatosis 5 (7-9). Several intraperitoneal (i.p.) RIT studies using strong energy beta or alpha emitters are ongoing in animals (8) (9) (10) (11) (12) (13) . So far, five antibodies (against MUC1, CA-125, TAG-72 and gp38) have been conjugated to four β-emitting radionuclides for i.p. RIT in patients with ovarian cancer (for review (14) ). Based on previous encouraging results ( [15] [16] [17] [18] [19] , a phase III randomized multicenter study was undertaken (20) in which the efficiency of conventional chemotherapy was compared with i.p. injection of 90 Y-labeled HMGF1 murine mAb (anti-MUC1). However no improvement in survival was observed after RIT, although peritoneal recurrence was significantly delayed. One explanation was that the irradiation dose delivered to the tumors was not high enough and that i.p. injection alone did not target all tumor deposits. Indeed, the induced toxicity by beta-and gamma-emitters is a drawback for a treatment scheme using repeated injections. One alternative could be the use of short range particles like alpha emitters (21) or Auger electron emitters. We previously showed that anti-CEA mAbs labeled with Auger electron emitters and intravenously (i.v.) injected in mice xenografted with cancer cells could significantly delay the growth of small peritoneal solid tumors (22, 23) . We thus wanted to assess the efficiency and toxicity of 125 I-mAbs when used in i.p. RIT in mice bearing small peritoneal tumors. In addition, since to our knowledge the effects of i.p. RIT carried out following the HIPEC protocol have never been investigated, we decided to carry out RIT using closed peritoneal perfusion of 125 I-labeled anti-CEA mAbs for a short period (1 h), followed by extensive washing of the peritoneal cavity with saline solution to remove the unbound radioactivity. We named this procedure brief-intraperitoneal RIT (Bip-RIT).
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MATERIALS AND METHODS
Cell line and monoclonal antibodies
The vulvar squamous carcinoma cell line A-431 expressing the Epidermal Growth Factor
Receptor (EGFR or HER1) and transfected as previously described in (22) , with constructs encoding the CarcinoEmbryonic Antigen (CEA) and luciferase genes was used. Cells were grown as described in (22) . The non-internalizing murine IgG1k 35A7 mAb, specific for the CEA Gold 2 epitope, was used to target CEA. The irrelevant PX antibody was used for control experiments. PX is an IgG1 mAb that has been purified from the mouse myeloma MOPC 21 (24) . PX and 35A7 were purified from mouse hybridoma ascite fluids by ammonium sulfate precipitation followed by ion exchange chromatography on DE52 cellulose (Whatman, Balston, United Kingdom).
Radiolabeling
Iodine 125 ( 125 I) was from Perkin Elmer (Boston, MA, USA) and mAbs were radiolabeled at the specific activity of 740 MBq/mg for RIT and biodistribution studies, using the IODO-GEN method and as described in (22) . The immunoreactivity of 125 I-mAbs against CEA was assessed in vitro by direct binding assay (22) . The binding percentage was determined by measuring the antigen-bound radioactivity after two washes with PBS and was between 50-60%.
Animals
Athymic nude mice (6-8 week/old females) were obtained from Charles River (Lyon, France) and were acclimated for 1 week before experimental use. They were housed at 22°C and 55% 
RIT experiments
Mice were i.p. grafted with 0.7 × 10 6 A-431 cells suspended in 0.3 ml DMEM medium.
Tumor growth was assessed 3 days after cell xenograft by bioluminescence imaging that allowed the segregation of mice in homogeneous groups. Four days following grafting, mice were treated by brief intraperitoneal radioimmunotherapy (Bip-RIT) or intraperitoneal RIT (ip-RIT).
The protocol used for Bip-RIT was as follows. Mice were anaesthetized by i.p. injection of a solution containing 100 mg/kg ketamine (Ketamine™ Panpharma; Panpharma, Fougère, France) and 1 mg/kg medetomidine (Dormitor™; Pfizer, Paris, France). Then, they were i.p.
injected with either NaCl or 125 I-mAbs in a final volume of 5 mL. One hour later, the peritoneal cavity was flushed with 25 mL NaCl for 15 min, using a perfusion system adapted from Aarts et al. (8) . Typically, an inflow needle was placed in the upper part of the abdominal cavity and two multiperforated catheters were inserted laterally through the abdominal wall to be used as outflows (Fig. 1A) . Perfusion was done using a peristaltic pump (Harvard apparatus, Les Ulis, France). Once the wash of the peritoneal cavity was terminated, the catheters were removed and mice were weighted. Mice were then awakened by i.p.
injection of atipamezole™ (Antisedan 2.5 mg/kg body weight, Pfizer, Paris, France).
Ip-RIT consisted of standard i.p. injections of saline solution (NaCl) or 125 I-mAbs (final volume of 5 mL) without wash of the peritoneal cavity and iv-RIT at day 7 or 11 was conventionally done as described in (22) .
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Specifically, for Bip-RIT, one group of mice (n=8) was treated with 5 mL of NaCl (Bip-NaCl ) and another (n=10) with 185MBq 125 I-35A7 mAb (Bip-125 I-35A7-RIT). In the case of ip-RIT, the control group (n=7) received one i.p. injection of 5mL NaCl (ip-NaCl), while the other group of mice (n=15) Tumor growth was followed weekly by bioluminescence imaging. Mice were sacrificed when the bioluminescence signal reached a value of 4.5× 10 7 photons/s corresponding to a total tumor weight of about 0.2-0.3g.
Bioluminescence and SPECT-CT imaging
In vivo bioluminescence imaging was performed following i.p. injection of luciferin (0.1 mg luciferin/g) as described in (22) . Whole-body SPECT/CT images were acquired at various times following Bip-125 I-35A7-RIT (0 h, 1 h, 24 h and 72 h) with a two-headed multiplexing multi-pinhole NanoSPECT (Bioscan Inc., Washington DC). 
Biodistribution experiments to mimic Bip-RIT and iv-RIT
Tumor weight assessment during RIT experiments
Since accurate direct measurement of the weight of peritoneal tumors could not be performed in RIT experiments due to the high activities and also because it would require sacrificing the mice, it was calculated from the weekly bioluminescence imaging data. For this purpose, biodistribution experiments were used to determine the calibration curve between the bioluminescence signal of tumors and their size. Typically, prior to sacrifice, tumors were imaged by bioluminescence and the corresponding signal (photon/s) was correlated with the calculated tumor weight (g) determined by direct measurement of the size of tumor nodules, as described in (22) . The calibration curve was similar to the one determined in our previous work (22) .
Uptake of radioactivity per organ and tumor and dosimetry
The uptake of radioactivity per tissue (expressed in Becquerel) in RIT experiments (UOR RIT ) was extrapolated from the uptake per tissue (UOR Biodis ) measured during the biodistribution experiments. Since the activities used in RIT experiments were 33 times higher than those used in the biodistribution analysis (185 MBq versus 5.5 MBq) for the same amount of injected mAbs (250 µg), all the UOR Biodis values were multiplied by 33 to mimic the therapeutic conditions. We considered that the weight of healthy tissues did not change all along the study period and that they did not differ between RIT and biodistribution experimental conditions. We confirmed that this assumption was true also for tumor nodules during the first week after injection. Therefore, the 33-fold correction was enough to determine the UOR RIT from UOR Biodis . The total cumulative decays per tissue, rs Ã , were calculated by measuring the area under the UOR RIT curves. Following the MIRD formalism (25) , the resulting values were multiplied by the S factor for determining the irradiation doses as described in (22) .
Statistical analysis
Kaplan-Meier survival estimates were calculated from the date of the xenograft until the date of the event of interest (i.e., a bioluminescence value of 4.5×10 7 photons/s) and compared with the Log-rank test. Statistical analysis was performed using the STATA 10.0 software.
RESULTS
Tumor growth
At day 4 after graft (just before starting the treatment), 5-6 nodules per mouse with a mean diameter of about 1.5-2 mm were detected by bioluminescence imaging. This corresponded to a mean tumor weight of 1.2±0.9 ×10 -2 g. In the Bip-NaCl group, tumors grew exponentially and all mice were sacrificed before day 40 after graft (Fig. 1B) . A similar growth rate was It is of note that the wash of the peritoneal cavity with NaCl slowed down tumor growth in the Bip-NaCl group compared to the ip-NaCl group (data not shown). This observation was further strengthened by the analysis of the survival data which was significantly lower after ip-NaCl (p<0.001, compare Fig. 3A with 3B ).
Toxicity of Bip-RIT using
125
I-mAbs
The residual activity per mouse was about 14.2 ±7.3 MBq immediately after the wash with saline solution and dropped to 2.1 ±0.7 MBq at 120h after Bip-RIT (Fig. 1C) . These results indicate that about 7.6% of the injected activity was effectively kept within the peritoneal cavity. No weight loss was observed after Bip-RIT (Suppl. Fig. 1 ). These results suggest that Bip-RIT is well tolerated by mice. However mild, transient hematological toxicity was reported in all treated mice in comparison to the control Bip-NaCl group (Fig. 2 and Suppl. Fig. 2 ). In the Bip-125 I-35A7-RIT group (Fig. 2) , the nadir for white blood cells (WBC) was reached between day 7 and 10 (around -20%) after graft. It was mainly due to decrease in lymphocytes and monocytes levels (-40%) (Suppl. Fig. 2 ). Platelet lowest point occurred slightly later (days 10-15, -30%), while no modification in red blood cells was observed.
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Most of the values returned to normal around day 39. In mice that received one intravenous injection of 125 I-mAbs at day 7 (Bip+ivd7-125 I-35A7-RIT, Bip+ivd7-125 I-PX-RIT), the decrease in WBC number was found to be more pronounced and prolonged (about -70% at day 22; Fig. 2) . When the i.v. injection was done at day 11 (Bip+ivd11-125 I-35A7-RIT) after graft, the hematological toxicity was in the same range but more prolonged in time and values
were not yet returned to baseline at day 39 ( Fig. 2 and Suppl. Fig. 2 ). For day 52, the ratio could not be calculated since most of the mice in the Bip-NaCl group had to be sacrificed due to tumor growth.
The similar effects observed in the Bip+ivd7-125 I-35A7-RIT and Bip+ivd7-125 I-PX-RIT mice suggest that the hematological toxicity was mainly due to non-specific irradiation, including soft X-rays or the most energetic electrons emitted by 125 I. In addition, ip+ipd7-125 I-35A7-RIT ( Fig. 2 and Suppl. Fig. 2 MBq was effectively remaining in mice. This result suggests that the high activity of 185
MBq maintained for one hour during Bip-RIT is mainly responsible for the hematological toxicity.
Bip-
I-35A7-RIT improves survival of mice
Mice were sacrificed when the bioluminescence signal reached 4. (Fig. 3A) . Moreover, one mouse in each of these two groups was cured at the end of the observation period of 100 d. Mice treated by Bip+ivd7-125 I-PX-RIT had an MS of 31 d rather similar to the control Bip-NaCl group (p = 0.188) (Fig. 3A) , suggesting the absence of toxicity/efficiency of 125 I when unbound to cells. 
SPECT-CT imaging after Bip-
125
I-35A7-RIT
Whole body SPECT-CT imaging showed that after injection, radioactivity was homogeneously distributed in the peritoneal cavity (Fig. 4A) . Following the wash of the peritoneal cavity the radioactivity concentrated at tumor nodules up to 3 d after injection (Fig.   4A ), as indicated by the good fitting with the bioluminescence signals (Fig. 4B) .
Bip-
125
I-35A7-RIT improves tumor-to-healthy tissues uptake ratio
The biodistribution study confirmed the strong uptake of 125 I-35A7 mAbs by tumor nodules (Fig. 5A) . The percentage of residual activity/g of tumor (%RA/g) immediately after the wash of the peritoneal cavity ranged between 72.1±30.2% at 1h and 20.5±4.8% at 168 h. These values were much higher than the peak value of 27.8±7.2% of injected activity/g of tumor (%IA/g) determined at 96h after a single i.v. injection of 37MBq (740MBq/mg), typical of intravenous 125 I-35A7-RIT (Fig. 5B) . Moreover, the uptake of radioactivity by healthy organs was higher after i.v. injection than after Bip-125 I-35A7-RIT. For instance, in Bip-125 I-35A7-Biodis mice, the peak value in blood was observed at 48 h and was 12.2±3.2 %RA/g, while it was about 28.1±2.4%IA/g in the iv-125 I-35A7-Biodis group at 1 h after injection (Fig. 5B ).
14 These results suggest that the Bip-125 I-35A7-RIT procedure improves tumor targeting and that healthy tissues are partially protected when compared to i.v. injection.
Cumulated uptake of radioactivity after Bip-
I-35A7-RIT and dosimetry
From the biodistribution data, subsequently we expressed the uptake of radioactivity (UOR) of 125 I-35A7 mAb by healthy organs and tumor nodules as a function of time ( Fig. 6A and 6B together with Suppl. Fig. 6A and 6B ).
The cumulated uptake of radioactivity ( rs Ã ) was then determined by calculating the area under the curves shown in Fig. 6A and 6B together with Suppl. 
DISCUSSION
In the present study, we have investigated the feasibility, toxicity and efficacy of brief intraperitoneal RIT (Bip-RIT) using a 125 I-mAb directed against CEA. This protocol is based on the HIPEC methodology, although hyperthermia was not associated with Bip-RIT. Our results indicate that about 7% of the injected activity, corresponding to about 14.2 MBq, was retained in the peritoneal cavity after washing. Mild and transient blood toxicity was observed and was mainly due to non-specific irradiation (possibly soft X-rays and more energetic electrons emitted by 125 I) that occurred during the one-hour peritoneal incubation with high activities of 125 I-mAbs. However, we estimated that in patients, about 300 µGy would be delivered by such an external irradiation at the sacrum level (data not shown). Therefore, the hematological toxicity is expected to be much lower than in mice. (14)). Therefore, although reducing the potential blood reservoir of 125 I-mAb in comparison to iv-RIT, the Bip-RIT procedure including the washing of the peritoneal cavity, eliminates undesirable radioactivity, and therefore it is less toxic.
SPECT-CT imaging of mice at different time points after
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The median survival of xenografted mice was significantly improved after Bip- However, the effect on survival was less strong than the improvement obtained after Remaining activity in each mouse after washing of the peritoneal cavity (1h after injection)
was determined by the biodistribution study. Values are the mean activity ± SD. 
